1. Letov 2.5 mg
Submitted to PTC of
Chulalongkorn Hospital
by Thamonwan Theerabunchorn
Medical Product Manager
2. AGENDA
Indication and Dosage Administration
Letov 2.5
- Active Ingredient Identification
- Pharmceutical Equivalance Proven
- Bioavialibility Equivalence Proven
- Stability : Accelerated &Long Term Stability
- World Wide-FDA approval
- Listed Hospital
Pharmaland Milestone
Zydus Cadilar Milestone
3. • Letrozole tablets is indicated for the adjuvant treatment
of postmenopausal women with hormone receptor
positive early breast cancer.
• Letrozole is indicated for first-line treatment of
postmenopausal women with hormone receptor positive
or hormone receptor unknown locally advanced or
metastatic breast cancer.
• Letrozole is also indicated for the treatment of advanced
breast cancer in postmenopausal women with disease
progression following antiestrogen therapy.
INDICATIONS
4. • The recommended dose of Letrozole is one 2.5
mg tablet administered once a day, without
regard to meals.
• In patients with advanced disease, treatment
with Letrozole should continue until tumor
progression is evident.
• No dose adjustment is required for elderly
patients. Patients treated with Letrozole do not
require glucocorticoid or mineralocorticoid
replacement therapy.
DOSAGE AND ADMINISTRATION
5. Renal Impairment
• No dosage adjustment is required for patients
with renal impairment if creatinine clearance is ≥
10 mL/min.
Hepatic Impairment
• No dosage adjustment is recommended for
patients with mild to moderate hepatic
impairment.
DOSAGE AND ADMINISTRATION
28. Reseach Methode
A
B
B
A
Reference
Test
Sequence I Sequence II
3 weeks
N = 28
Single Dose randomized, two treatment, two period,
two sequence cross over design
with a 3 WEEKS wash out period
Study Design
50. Manufacture Profile
• TOP 4 Pharmaceutical Company
• WHO GMP from US FDA
• More than 6,000 staffs
• More than 80 staff of Scienctist and R&D
• Produce more than 300 Items
59. Efficacy proven study
- Letrozole in Early Stage Breast Cancer
- Letrozole in Advanced Stage Breast Cancer
- Letrozole in Metastatis Breast Cancer
Safety and Tolerability study